Review of the Published Literature Confirms the Safety of Intravenous
Infusion of Mesenchymal Stem Cells

Amir      Barmada; Joshua      Sharan; Nicolas      Band; Tobias      Rumschlag; Arwah      Yaqub; Eliana      Liebman; Chadwick      Prodromos
doi:10.2174/1574888X17666220823092202
Abstract

Background: Mesenchymal stem cells (MSCs) have been shown to decrease inflammation and enhance healing due to their immunomodulatory properties and secretion of growth factors. Intravenous infusion is the most common delivery route of MSCs, and it is used for the treatment of a wide variety of conditions, with established efficacy.
Objective: This review will analyze the safety of intravenous infusion of MSCs and determine the incidence of any possible resultant Serious Adverse Events (SAEs).
Methods: Using PubMed, we searched the scientific literature to identify SAEs related to intravenous infusion of MSCs. We performed disease-specific searches and a general adverse event search.
Results: A total of 70 studies were included in this review. Thousands of infusions were administered and only two SAEs were identified from the same study. The SAEs were two upper extremity thromboembolisms in patients with preexisting renal disease.
Conclusion: Properly performed intravenous infusion of MSCs is very safe, with a near absence of reported serious adverse events associated with its use.
Keywords: Mesenchymal stem cell, intravenous infusion, inflammation, serious adverse events, rheumatoid arthritis, stem cell treatment.
« Previous Next »
Graphical Abstract

[1]
Lin W, Xu L, Zwingenberger S, Gibon E, Goodman SB, Li G. Mesenchymal stem cells homing to improve bone healing. J Orthop Translat  2017; 9: 19-27.
 [http://dx.doi.org/10.1016/j.jot.2017.03.002] [PMID:  29662796]

[2]
Fu X, Liu G, Halim A, Ju Y, Luo Q, Song AG. Mesenchymal stem cell migration and tissue repair. Cells  2019; 8(8): 784.
 [http://dx.doi.org/10.3390/cells8080784] [PMID:  31357692]

[3]
Murphy MB, Moncivais K, Caplan AI. Mesenchymal stem cells: Environmentally responsive therapeutics for regenerative medicine. Exp Mol Med  2013; 45(11): e54.
 [http://dx.doi.org/10.1038/emm.2013.94] [PMID:  24232253]

[4]
Wang L, Li Y, Xu M, et al. Regulation of inflammatory cytokine storms by mesenchymal stem cells. Front Immunol  2021; 12: 726909.
 [http://dx.doi.org/10.3389/fimmu.2021.726909] [PMID:  34394132]

[5]
Connick P, Kolappan M, Crawley C, et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: An open-label phase 2a proof-of-concept study. Lancet Neurol  2012; 11(2): 150-6.
 [http://dx.doi.org/10.1016/S1474-4422(11)70305-2] [PMID:  22236384]

[6]
Li JF, Zhang DJ, Geng T, et al. The potential of human umbilical cord-derived mesenchymal stem cells as a novel cellular therapy for multiple sclerosis. Cell Transplant  2014; 23 (Suppl. 1): 113-22.
 [http://dx.doi.org/10.3727/096368914X685005] [PMID:  25385295]

[7]
Gu F, Wang D, Zhang H, et al. Allogeneic mesenchymal stem cell transplantation for lupus nephritis patients refractory to conventional therapy. Clin Rheumatol  2014; 33(11): 1611-9.
 [http://dx.doi.org/10.1007/s10067-014-2754-4] [PMID:  25119864]

[8]
Liang J, Zhang H, Hua B, et al. Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: A pilot clinical study. Ann Rheum Dis  2010; 69(8): 1423-9.
 [http://dx.doi.org/10.1136/ard.2009.123463] [PMID:  20650877]

[9]
Sun L, Akiyama K, Zhang H, et al. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells  2009; 27(6): 1421-32.
 [http://dx.doi.org/10.1002/stem.68] [PMID:  19489103]

[10]
Zhang J, Lv S, Liu X, Song B, Shi L. Umbilical cord mesenchymal stem cell treatment for crohn’s disease: A randomized controlled clinical trial. Gut Liver  2018; 12(1): 73-8.
 [http://dx.doi.org/10.5009/gnl17035] [PMID:  28873511]

[11]
Gu J, Huang L, Zhang C, et al. Therapeutic evidence of umbilical cord-derived mesenchymal stem cell transplantation for cerebral palsy: A randomized, controlled trial. Stem Cell Res Ther  2020; 11(1): 43.
 [http://dx.doi.org/10.1186/s13287-019-1545-x] [PMID:  32014055]

[12]
Guo Y, Tian X, Wang X, Xiao Z. Adverse effects of immunoglobulin therapy. Front Immunol  2018; 9: 1299.
 [http://dx.doi.org/10.3389/fimmu.2018.01299] [PMID:  29951056]

[13]
Padayatty SJ, Sun AY, Chen Q, et al. Intravenous use by complementary and alternative medicine practitioners and adverse effects. PLoS One  2010; 5(7): e11414.
 [http://dx.doi.org/10.1371/journal.pone.0011414] [PMID:  20628650]

[14]
Froessler B, Gajic T, Dekker G, Hodyl NA. Treatment of iron deficiency and iron deficiency anemia with intravenous ferric carboxymaltose in pregnancy. Arch Gynecol Obstet  2018; 298(1): 75-82.
 [http://dx.doi.org/10.1007/s00404-018-4782-9] [PMID:  29740690]

[15]
Prodromos C, Rumschlag T. Administration of autologous mesenchymal cells for the treatment of arthritis. Curr Stem Cell Res Ther  2021; 16(8): 931-8.
 [http://dx.doi.org/10.2174/1574888X16666210224145104] [PMID:  33655846]

[16]
Siwek T, Jezierska-Woźniak K, Maksymowicz S, et al. Repeat administration of bone marrow-derived mesenchymal stem cells for treatment of amyotrophic lateral sclerosis. Med Sci Monit  2020; 26: e927484.
 [http://dx.doi.org/10.12659/MSM.927484] [PMID:  33301428]

[17]
Oh KW, Moon C, Kim HY, et al. Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in amyotrophic lateral sclerosis. Stem Cells Transl Med  2015; 4(6): 590-7.
 [http://dx.doi.org/10.5966/sctm.2014-0212] [PMID:  25934946]

[18]
Mohyeddin Bonab M, Ali Sahraian M, Aghsaie A, et al. Autologous mesenchymal stem cell therapy in progressive multiple sclerosis: An open label study. Curr Stem Cell Res Ther  2012; 7(6): 407-14.
 [http://dx.doi.org/10.2174/157488812804484648] [PMID:  23061813]

[19]
Tian C, Wang X, Wang X, et al. Autologous bone marrow mesenchymal stem cell therapy in the subacute stage of traumatic brain injury by lumbar puncture. Exp Clin Transplant  2013; 11(2): 176-81.
 [http://dx.doi.org/10.6002/ect.2012.0053] [PMID:  22891928]

[20]
Sharifzadeh N, Ghasemi A, Tavakol Afshari J, et al. Intrathecal autologous bone marrow stem cell therapy in children with autism: A randomized controlled trial. Asia-Pac Psychiatry  2021; 13(2): e12445.
 [http://dx.doi.org/10.1111/appy.12445] [PMID:  33150703]

[21]
Dahbour S, Jamali F, Alhattab D, et al. Mesenchymal stem cells and conditioned media in the treatment of multiple sclerosis patients: Clinical, ophthalmological and radiological assessments of safety and efficacy. CNS Neurosci Ther  2017; 23(11): 866-74.
 [http://dx.doi.org/10.1111/cns.12759] [PMID:  28961381]

[22]
Barczewska M, Maksymowicz S, Zdolińska-Malinowska I, Siwek T, Grudniak M. Umbilical cord mesenchymal stem cells in amyotrophic lateral sclerosis: An original study. Stem Cell Rev Rep  2020; 16(5): 922-32.
 [http://dx.doi.org/10.1007/s12015-020-10016-7] [PMID:  32725316]

[23]
Oh KW, Noh MY, Kwon MS, et al. Repeated intrathecal mesenchymal stem cells for amyotrophic lateral sclerosis. Ann Neurol  2018; 84(3): 361-73.
 [http://dx.doi.org/10.1002/ana.25302] [PMID:  30048006]

[24]
Llufriu S, Sepúlveda M, Blanco Y, et al. Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis. PLoS One  2014; 9(12): e113936.
 [http://dx.doi.org/10.1371/journal.pone.0113936] [PMID:  25436769]

[25]
Cohen JA, Imrey PB, Planchon SM, et al. Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis. Mult Scler  2018; 24(4): 501-11.
 [http://dx.doi.org/10.1177/1352458517703802] [PMID:  28381130]

[26]
Fernández O, Izquierdo G, Fernández V, et al. Research Group Study EudraCT 2008-004015-35. Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study. PLoS One  2018; 13(5): e0195891.
 [http://dx.doi.org/10.1371/journal.pone.0195891] [PMID:  29768414]

[27]
Riordan NH, Morales I, Fernández G, et al. Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis. J Transl Med  2018; 16(1): 57.
 [http://dx.doi.org/10.1186/s12967-018-1433-7] [PMID:  29523171]

[28]
Petrou P, Kassis I, Levin N, et al. Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis. Brain  2020; 143(12): 3574-88.
 [http://dx.doi.org/10.1093/brain/awaa333] [PMID:  33253391]

[29]
Karussis D, Karageorgiou C, Vaknin-Dembinsky A, et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol  2010; 67(10): 1187-94.
 [http://dx.doi.org/10.1001/archneurol.2010.248] [PMID:  20937945]

[30]
Odinak MM, Bisaga GN, Novitskiĭ AV, et al. Transplantation of mesenchymal stem cells in multiple sclerosis. Zh Nevrol Psikhiatr Im S S Korsakova  2011; 111(2 Pt 2): 72-6.

[31]
Lublin FD, Bowen JD, Huddlestone J, et al. Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: A randomized, placebo-controlled, multiple-dose study. Mult Scler Relat Disord  2014; 3(6): 696-704.
 [http://dx.doi.org/10.1016/j.msard.2014.08.002] [PMID:  25891548]

[32]
Wang L, Wang L, Cong X, et al. Human umbilical cord mesenchymal stem cell therapy for patients with active rheumatoid arthritis: Safety and efficacy. Stem Cells Dev  2013; 22(24): 3192-202.
 [http://dx.doi.org/10.1089/scd.2013.0023] [PMID:  23941289]

[33]
Liang J, Li X, Zhang H, et al. Allogeneic mesenchymal stem cells transplantation in patients with refractory RA. Clin Rheumatol  2012; 31(1): 157-61.
 [http://dx.doi.org/10.1007/s10067-011-1816-0] [PMID:  21837432]

[34]
Wang L, Huang S, Li S, et al. Efficacy and safety of umbilical cord mesenchymal stem cell therapy for rheumatoid arthritis patients: A prospective phase I/II study. Drug Des Devel Ther  2019; 13: 4331-40.
 [http://dx.doi.org/10.2147/DDDT.S225613] [PMID:  31908418]

[35]
Ghoryani M, Shariati-Sarabi Z, Tavakkol-Afshari J, Mohammadi M. The sufficient immunoregulatory effect of autologous bone marrow-derived mesenchymal stem cell transplantation on regulatory T cells in patients with refractory rheumatoid arthritis. J Immunol Res  2020; 2020: 1-8.
 [http://dx.doi.org/10.1155/2020/3562753] [PMID:  32411794]

[36]
Yang Y, He X, Zhao R, et al. Serum IFN-γ levels predict the therapeutic effect of mesenchymal stem cell transplantation in active rheumatoid arthritis. J Transl Med  2018; 16(1): 165.
 [http://dx.doi.org/10.1186/s12967-018-1541-4] [PMID:  29903026]

[37]
Park EH, Lim H, Lee S, et al. Intravenous infusion of umbilical cord blood-derived mesenchymal stem cells in rheumatoid arthritis: A phase ia clinical trial. Stem Cells Transl Med  2018; 7(9): 636-42.
 [http://dx.doi.org/10.1002/sctm.18-0031] [PMID:  30112846]

[38]
Ghoryani M, Shariati-Sarabi Z, Tavakkol-Afshari J, Ghasemi A, Poursamimi J, Mohammadi M. Amelioration of clinical symptoms of patients with refractory rheumatoid arthritis following treatment with autologous bone marrow-derived mesenchymal stem cells: A successful clinical trial in Iran. Biomed Pharmacother  2019; 109: 1834-40.
 [http://dx.doi.org/10.1016/j.biopha.2018.11.056] [PMID:  30551438]

[39]
Wang D, Li J, Zhang Y, et al. Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: A multicenter clinical study. Arthritis Res Ther  2014; 16(2): R79.
 [http://dx.doi.org/10.1186/ar4520] [PMID:  24661633]

[40]
Wang D, Zhang H, Liang J, et al. Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience. Cell Transplant  2013; 22(12): 2267-77.
 [http://dx.doi.org/10.3727/096368911X582769c] [PMID:  24388428]

[41]
Yang GX, Pan LP, Zhou QY, et al. Therapeutic effects of umbilical cord mesenchymal stem cells transplantation on systemic lupus erythematosus. Sichuan Da Xue Xue Bao Yi Xue Ban  2014; 45(2): 338-41.

[42]
Wang D, Akiyama K, Zhang H, et al. Double allogenic mesenchymal stem cells transplantations could not enhance therapeutic effect compared with single transplantation in systemic lupus erythematosus. Clin Dev Immunol  2012; 2012: 1-7.
 [http://dx.doi.org/10.1155/2012/273291] [PMID:  22829849]

[43]
Hashemian SMR, Aliannejad R, Zarrabi M, et al. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: A case series. Stem Cell Res Ther  2021; 12(1): 91.
 [http://dx.doi.org/10.1186/s13287-021-02165-4] [PMID:  33514427]

[44]
Meng F, Xu R, Wang S, et al. Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: A phase 1 clinical trial. Signal Transduct Target Ther  2020; 5(1): 172.
 [http://dx.doi.org/10.1038/s41392-020-00286-5] [PMID:  32855385]

[45]
Wilson JG, Liu KD, Zhuo H, et al. Mesenchymal stem (stromal) cells for treatment of ARDS: A phase 1 clinical trial. Lancet Respir Med  2015; 3(1): 24-32.
 [http://dx.doi.org/10.1016/S2213-2600(14)70291-7] [PMID:  25529339]

[46]
Zheng G, Huang L, Tong H, et al. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: A randomized, placebo-controlled pilot study. Respir Res  2014; 15(1): 39.
 [http://dx.doi.org/10.1186/1465-9921-15-39] [PMID:  24708472]

[47]
Lanzoni G, Linetsky E, Correa D, et al. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial. Stem Cells Transl Med  2021; 10(5): 660-73.
 [http://dx.doi.org/10.1002/sctm.20-0472] [PMID:  33400390]

[48]
Yip HK, Fang WF, Li YC, et al. Human umbilical cord-derived mesenchymal stem cells for acute respiratory distress syndrome. Crit Care Med  2020; 48(5): e391-9.
 [http://dx.doi.org/10.1097/CCM.0000000000004285] [PMID:  32187077]

[49]
Duijvestein M, Vos ACW, Roelofs H, et al. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn’s disease: Results of a phase I study. Gut  2010; 59(12): 1662-9.
 [http://dx.doi.org/10.1136/gut.2010.215152] [PMID:  20921206]

[50]
Dhere T, Copland I, Garcia M, et al. The safety of autologous and metabolically fit bone marrow mesenchymal stromal cells in medically refractory Crohn’s disease - a phase 1 trial with three doses. Aliment Pharmacol Ther  2016; 44(5): 471-81.
 [http://dx.doi.org/10.1111/apt.13717] [PMID:  27385373]

[51]
Chung JW, Chang WH, Bang OY, et al. Efficacy and safety of intravenous mesenchymal stem cells for ischemic stroke. Neurology  2021; 96(7): e1012-23.
 [http://dx.doi.org/10.1212/WNL.0000000000011440] [PMID:  33472925]

[52]
Levy ML, Crawford JR, Dib N, Verkh L, Tankovich N, Cramer SC. Phase I/II study of safety and preliminary efficacy of intravenous allogeneic mesenchymal stem cells in chronic stroke. Stroke  2019; 50(10): 2835-41.
 [http://dx.doi.org/10.1161/STROKEAHA.119.026318] [PMID:  31495331]

[53]
Fang J, Guo Y, Tan S, et al. Autologous endothelial progenitor cells transplantation for acute ischemic stroke: A 4-year follow-up study. Stem Cells Transl Med  2019; 8(1): 14-21.
 [http://dx.doi.org/10.1002/sctm.18-0012] [PMID:  30156755]

[54]
Glassberg MK, Minkiewicz J, Toonkel RL, et al. Allogeneic human mesenchymal stem cells in patients with idiopathic pulmonary fibrosis via intravenous delivery (AETHER). Chest  2017; 151(5): 971-81.
 [http://dx.doi.org/10.1016/j.chest.2016.10.061] [PMID:  27890713]

[55]
Averyanov A, Koroleva I, Konoplyannikov M, et al. First-in-human high-cumulative-dose stem cell therapy in idiopathic pulmonary fibrosis with rapid lung function decline. Stem Cells Transl Med  2020; 9(1): 6-16.
 [http://dx.doi.org/10.1002/sctm.19-0037] [PMID:  31613055]

[56]
Chambers DC, Enever D, Ilic N, et al. A phase 1b study of placenta-derived mesenchymal stromal cells in patients with idiopathic pulmonary fibrosis. Respirology  2014; 19(7): 1013-8.
 [http://dx.doi.org/10.1111/resp.12343] [PMID:  25039426]

[57]
Tompkins BA, DiFede DL, Khan A, et al. Allogeneic mesenchymal stem cells ameliorate aging frailty: A phase II randomized, double-blind, placebo-controlled clinical trial. J Gerontol A Biol Sci Med Sci  2017; 72(11): 1513-22.
 [http://dx.doi.org/10.1093/gerona/glx137] [PMID:  28977399]

[58]
Golpanian S, DiFede DL, Khan A, et al. Allogeneic human mesenchymal stem cell infusions for aging frailty. J Gerontol A Biol Sci Med Sci  2017; 72(11): 1505-12.
 [http://dx.doi.org/10.1093/gerona/glx056] [PMID:  28444181]

[59]
Lee PH, Kim JW, Bang OY, Ahn YH, Joo IS, Huh K. Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy. Clin Pharmacol Ther  2008; 83(5): 723-30.
 [http://dx.doi.org/10.1038/sj.clpt.6100386] [PMID:  17898702]

[60]
Lee PH, Lee JE, Kim HS, et al. A randomized trial of mesenchymal stem cells in multiple system atrophy. Ann Neurol  2012; 72(1): 32-40.
 [http://dx.doi.org/10.1002/ana.23612] [PMID:  22829267]

[61]
He X, Ai S, Guo W, et al. Umbilical cord-derived mesenchymal stem (stromal) cells for treatment of severe sepsis: Aphase 1 clinical trial. Transl Res  2018; 199: 52-61.
 [http://dx.doi.org/10.1016/j.trsl.2018.04.006] [PMID:  30044959]

[62]
McIntyre LA, Stewart DJ, Mei SHJ, et al. Cellular immunotherapy for septic shock. A phase I clinical trial. Am J Respir Crit Care Med  2018; 197(3): 337-47.
 [http://dx.doi.org/10.1164/rccm.201705-1006OC] [PMID:  28960096]

[63]
Skyler JS, Fonseca VA, Segal KR, Rosenstock J. Allogeneic mesenchymal precursor cells in type 2 diabetes: A randomized, placebo-controlled, dose-escalation safety and tolerability pilot study. Diabetes Care  2015; 38(9): 1742-9.
 [http://dx.doi.org/10.2337/dc14-2830] [PMID:  26153271]

[64]
Packham DK, Fraser IR, Kerr PG, Segal KR. Allogeneic Mesenchymal Precursor Cells (MPC) in diabetic nephropathy: A randomized, placebo-controlled, dose escalation study. EBioMedicine  2016; 12: 263-9.
 [http://dx.doi.org/10.1016/j.ebiom.2016.09.011] [PMID:  27743903]

[65]
Lee SE, Lee SJ, Kim SE, et al. Intravenous allogeneic umbilical cord blood–derived mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa patients. JCI Insight  2021; 6(2): e143606.
 [http://dx.doi.org/10.1172/jci.insight.143606] [PMID:  33491668]

[66]
Rashidghamat E, Kadiyirire T, Ayis S, et al. Phase I/II open-label trial of intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa. J Am Acad Dermatol  2020; 83(2): 447-54.
 [http://dx.doi.org/10.1016/j.jaad.2019.11.038] [PMID:  31786163]

[67]
Huang L, Zhang C, Gu J, et al. A randomized, placebo-controlled trial of human umbilical cord blood mesenchymal stem cell infusion for children with cerebral palsy. Cell Transplant  2018; 27(2): 325-34.
 [http://dx.doi.org/10.1177/0963689717729379] [PMID:  29637820]

[68]
Skrahin A, Ahmed RK, Ferrara G, et al. Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: An open-label phase 1 safety trial. Lancet Respir Med  2014; 2(2): 108-22.
 [http://dx.doi.org/10.1016/S2213-2600(13)70234-0] [PMID:  24503266]

[69]
Pelizzo G, Avanzini MA, Lenta E, et al. Allogeneic mesenchymal stromal cells: Novel therapeutic option for mutated FLNA‐associated respiratory failure in the pediatric setting. Pediatr Pulmonol  2020; 55(1): 190-7.
 [http://dx.doi.org/10.1002/ppul.24497] [PMID:  31468740]

[70]
Chambers DC, Enever D, Lawrence S, et al. Mesenchymal stromal cell therapy for chronic lung allograft dysfunction: Results of a first-in-man study. Stem Cells Transl Med  2017; 6(4): 1152-7.
 [http://dx.doi.org/10.1002/sctm.16-0372] [PMID:  28186707]

[71]
Rushkevich YN, Kosmacheva SM, Zabrodets GV, et al. The use of autologous mesenchymal stem cells for cell therapy of patients with amyotrophic lateral sclerosis in Belarus. Bull Exp Biol Med  2015; 159(4): 576-81.
 [http://dx.doi.org/10.1007/s10517-015-3017-3] [PMID:  26395626]

[72]
Fu Y, Yan Y, Qi Y, et al. Impact of autologous mesenchymal stem cell infusion on neuromyelitis optica spectrum disorder: A pilot, 2-year observational study. CNS Neurosci Ther  2016; 22(8): 677-85.
 [http://dx.doi.org/10.1111/cns.12559] [PMID:  27219819]

[73]
Liang J, Zhang H, Zhao C, et al. Effects of allogeneic mesenchymal stem cell transplantation in the treatment of liver cirrhosis caused by autoimmune diseases. Int J Rheum Dis  2017; 20(9): 1219-26.
 [http://dx.doi.org/10.1111/1756-185X.13015] [PMID:  28217916]

[74]
De Jesus MM, Santiago JS, Trinidad CV, et al. Autologous adipose-derived mesenchymal stromal cells for the treatment of psoriasis vulgaris and psoriatic arthritis: A case report. Cell Transplant  2016; 25(11): 2063-9.
 [http://dx.doi.org/10.3727/096368916X691998] [PMID:  27301844]

[75]
Reinders MEJ, de Fijter JW, Roelofs H, et al. Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: Results of a phase I study. Stem Cells Transl Med  2013; 2(2): 107-11.
 [http://dx.doi.org/10.5966/sctm.2012-0114] [PMID:  23349326]

[76]
Butler J, Epstein SE, Greene SJ, et al. Intravenous allogeneic mesenchymal stem cells for nonischemic cardiomyopathy. Circ Res  2017; 120(2): 332-40.
 [http://dx.doi.org/10.1161/CIRCRESAHA.116.309717] [PMID:  27856497]

[77]
Makhlough A, Shekarchian S, Moghadasali R, et al. Safety and tolerability of autologous bone marrow mesenchymal stromal cells in ADPKD patients. Stem Cell Res Ther  2017; 8(1): 116.
 [http://dx.doi.org/10.1186/s13287-017-0557-7] [PMID:  28535817]

[78]
Wu Z, Zhang S, Zhou L, et al. Thromboembolism induced by umbilical cord mesenchymal stem cell infusion: A report of two cases and literature review. Transplant Proc  2017; 49(7): 1656-8.
 [http://dx.doi.org/10.1016/j.transproceed.2017.03.078] [PMID:  28838459]

[79]
Chen S, Zhao K, Lin R, et al. The efficacy of mesenchymal stem cells in bronchiolitis obliterans syndrome after allogeneic HSCT: A multicenter prospective cohort study. EBioMedicine  2019; 49: 213-22.
 [http://dx.doi.org/10.1016/j.ebiom.2019.09.039] [PMID:  31668569]

[80]
Jin JL, Liu Z, Lu ZJ, et al. Safety and efficacy of umbilical cord mesenchymal stem cell therapy in hereditary spinocerebellar ataxia. Curr Neurovasc Res  2013; 10(1): 11-20.
 [http://dx.doi.org/10.2174/156720213804805936] [PMID:  23151076]

[81]
Lv YT, Zhang Y, Liu M, et al. Transplantation of human cord blood mononuclear cells and umbilical cord-derived mesenchymal stem cells in autism. J Transl Med  2013; 11(1): 196.
 [http://dx.doi.org/10.1186/1479-5876-11-196] [PMID:  23978163]

[82]
Wang Z, Luo Y, Chen L, Liang W. Safety of neural stem cell transplantation in patients with severe traumatic brain injury. Exp Ther Med  2017; 13(6): 3613-8.
 [http://dx.doi.org/10.3892/etm.2017.4423] [PMID:  28588689]

[83]
Chullikana A, Majumdar AS, Gottipamula S, et al. Randomized, double-blind, phase I/II study of intravenous allogeneic mesenchymal stromal cells in acute myocardial infarction. Cytotherapy  2015; 17(3): 250-61.
 [http://dx.doi.org/10.1016/j.jcyt.2014.10.009] [PMID:  25484310]

[84]
Ra JC, Shin IS, Kim SH, et al. Safety of intravenous infusion of human adipose tissue-derived mesenchymal stem cells in animals and humans. Stem Cells Dev  2011; 20(8): 1297-308.
 [http://dx.doi.org/10.1089/scd.2010.0466] [PMID:  21303266]

[85]
Weiss DJ, Casaburi R, Flannery R, LeRoux-Williams M, Tashkin DP. A placebo-controlled, randomized trial of mesenchymal stem cells in COPD. Chest  2013; 143(6): 1590-8.
 [http://dx.doi.org/10.1378/chest.12-2094] [PMID:  23172272]

[86]
Wang P, Li Y, Huang L, et al. Effects and safety of allogenic mesenchymal stem cell intravenous infusion in active ankylosing spondylitis patients who failed NSAIDs: A 20-week clinical trial. Cell Transplant  2014; 23(10): 1293-303.
 [http://dx.doi.org/10.3727/096368913X667727] [PMID:  23711393]

[87]
Lu Z, Wang F, Liang M. SerpinC1/Antithrombin III in kidney-related diseases. Clin Sci (Lond)  2017; 131(9): 823-31.
 [http://dx.doi.org/10.1042/CS20160669] [PMID:  28424376]
Rights & Permissions Print Cite
Article Metrics
54
2
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/1574888X17666220823092202	Print ISSN 1574-888X
Publisher Name Bentham Science Publisher	Online ISSN 2212-3946
Current Stem Cell Research & Therapy

Review of the Published Literature Confirms the Safety of Intravenous Infusion of Mesenchymal Stem Cells

Abstract

Graphical Abstract

Related Journals

Related Books

Related Articles
